Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice
Hao Hu, Pavel Zakharov, Orion J. Peterson, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 49, pp. 31319-31330
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Golnaz Morad, Beth A. Helmink, Padmanee Sharma, et al.
Cell (2021) Vol. 184, Iss. 21, pp. 5309-5337
Open Access | Times Cited: 1070
Immunologic tumor microenvironment modulators for turning cold tumors hot
Gholamreza Khosravi, Samaneh Mostafavi, Sanaz Bastan, et al.
Cancer Communications (2024) Vol. 44, Iss. 5, pp. 521-553
Open Access | Times Cited: 61
The immunology of type 1 diabetes
Kevan C. Herold, Thomas Delong, Ana Luisa Perdigoto, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 6, pp. 435-451
Open Access | Times Cited: 47
Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade
Emi Kawada-Horitani, Shunbun Kita, Tomonori Okita, et al.
Diabetologia (2022) Vol. 65, Iss. 7, pp. 1185-1197
Open Access | Times Cited: 45
Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
Dávid Dóra, Syeda Mahak Zahra Bokhari, Kenan Aloss, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2769-2769
Open Access | Times Cited: 26
Inflammation versus regulation: how interferon-gamma contributes to type 1 diabetes pathogenesis
David J. De George, Tingting Ge, Balasubramaniam Krishnamurthy, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 24
CXCL16-dependent scavenging of oxidized lipids by islet macrophages promotes differentiation of pathogenic CD8+ T cells in diabetic autoimmunity
Neetu Srivastava, Hao Hu, Orion J. Peterson, et al.
Immunity (2024) Vol. 57, Iss. 7, pp. 1629-1647.e8
Open Access | Times Cited: 9
TCL1A in naïve B cells as a therapeutic target for type 1 diabetes
Siweier Luo, Lína Zhang, Chunfang Wei, et al.
EBioMedicine (2025) Vol. 113, pp. 105593-105593
Closed Access | Times Cited: 1
Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression
Jian Lu, Jing Wu, Lingxiang Mao, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 67, pp. 58-65
Closed Access | Times Cited: 35
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection
Derek VanDyke, Marcos Iglesias, Jakub Tomala, et al.
Cell Reports (2022) Vol. 41, Iss. 3, pp. 111478-111478
Open Access | Times Cited: 32
Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes
Ana Luisa Perdigoto, Songyan Deng, Katherine Du, et al.
JCI Insight (2022) Vol. 7, Iss. 17
Open Access | Times Cited: 28
Inflammatory Cell Infiltration Into Islets Without PD-L1 Expression Is Associated With the Development of Immune Checkpoint Inhibitor–Related Type 1 Diabetes in Genetically Susceptible Patients
Satoshi Kawata, Junji Kozawa, S. Yoneda, et al.
Diabetes (2023) Vol. 72, Iss. 4, pp. 511-519
Open Access | Times Cited: 17
Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice
Yun Kyung Cho, Chang Hee Jung
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 6, pp. 757-766
Open Access | Times Cited: 16
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Xuwen Lin, Mei Xie, Jie Yao, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 5
Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism
Diane Mourad, Nadim S. Azar, Assaad A. Eid, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 2093-2093
Open Access | Times Cited: 27
Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice
Jenna L. Collier, Kristen E. Pauken, Catherine Lee, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 10
Open Access | Times Cited: 12
Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
Kaili Yang, Jiarui Li, Zhao Sun, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 7, pp. 3907-3918
Closed Access | Times Cited: 11
Type I Diabetes—A Rare Adverse Event Described in Patients Receiving Immunotherapy Versus a Side Effect from SARS-CoV-2 Infection
Raluca-Ileana Pătru, Miruna Ghigeanu, Maria-Alexandra Barbu, et al.
Reports — Medical Cases Images and Videos (2025) Vol. 8, Iss. 1, pp. 31-31
Open Access
Tissue Resident and Infiltrating Immune Cells: Their Influence on the Demise of Beta Cells in Type 1 Diabetes
Sophie Walker, Pia Leete, Joanne Boldison
Biomolecules (2025) Vol. 15, Iss. 3, pp. 441-441
Open Access
Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors
Anna Arecco, Cristian Petolicchio, Alessandro Pastorino, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Gluten‐Free Diet Induces Small‐Scale Changes Across Multiple T‐Cell Subsets in NOD Mice
Veronika Niederlová, Juraj Michálik, Barbora Drabonova, et al.
European Journal of Immunology (2025) Vol. 55, Iss. 4
Open Access
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Daniel Rönen, Aseel Bsoul, Michal Lotem, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 540-540
Open Access | Times Cited: 18
Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature
Peng Ning, Shilan Liu, Hongyi Cao
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes
Prerak Trivedi, Gaurang Jhala, David J. De George, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Altering β Cell Antigen Exposure to Exhausted CD8+ T Cells Prevents Autoimmune Diabetes in Mice
David J. De George, Gaurang Jhala, Claudia Selck, et al.
The Journal of Immunology (2024) Vol. 212, Iss. 11, pp. 1658-1669
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top